SCHEMBL9976718

SCHEMBL9976718

CCCCCCCCCCCCn1c2ccc(F)cc2c2cc3c(cc21)c1cc(F)ccc1n3CCCCCCCCCCCC

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 7/20 0.53
PSEN2 P49810 7/20 0.53
APH1B Q8WW43 7/20 0.53
NCSTN Q92542 7/20 0.53
APH1A Q96BI3 7/20 0.53
PSENEN Q9NZ42 7/20 0.53
ICMT O60725 3/20 0.51
CNR2 P34972 5/20 0.50
PER2 O15055 1/20 0.48
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PGR P06401 2/20 0.43
RORA P35398 1/20 0.43
RORC P51449 1/20 0.43
RORB Q92753 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9976729 0.93 RORA (0.51) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8148630 0.90 MAPT (0.54) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18268247 0.87 ICMT (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL19885203 0.84 ALDH1A1 (0.48) ICMTCNR2PER2ALDH1A1LMNA
SCHEMBL8143242 0.83 MAPT (0.52) PER2ALDH1A1LMNAGAAMAPT
SCHEMBL13125230 0.82 RORA (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL28014993 0.81 PSEN1 (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL551120 0.81 PSEN1 (0.77) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL926107 0.81 PSEN1 (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL9976723 0.80 PSEN1 (0.62) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140088313-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2014-03-27 US disclosed
US-20140088313-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2014-03-27 US disclosed
US-20120157689-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2012-06-21 US disclosed
US-8110690-B2 Substituted indolocarbazoles XEROX CORPORATION (US) 2012-02-07 US disclosed
US-20090036689-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2009-02-05 US disclosed
US-7456424-B2 Thin film transistors including indolocarbozoles XEROX CORPORATION (US) 2008-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036689-A1 SUBSTITUTED INDOLOCARBAZOLES HTR3C, HTR3A, AANAT PSEN1 3162/4885PSEN2 1766/4885APH1B 4134/4885
US-20120157689-A1 SUBSTITUTED INDOLOCARBAZOLES HTR3C, HTR3A, AANAT PSEN1 3162/4885PSEN2 1766/4885APH1B 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.